PAP
AVBP icon

Persistent Asset Partners’s ArriVent BioPharma AVBP Stock Holding History

Persistent Asset Partners’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$547K Buy
15,734
+7,626
+94% +$225K 0.16% 102
2026
Q1 		$187K Buy
8,108
+145
+2% +$3.27K 0.07% 199
2025
Q4 		$160K Buy
+7,963
New +$166K 0.07% 237

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Persistent Asset Partners's AVBP Position: Q2 2026 in Review

Persistent Asset Partners increased its ArriVent BioPharma (AVBP) stake by 94% in Q2 2026, buying an estimated $225K and bringing the position to 15,734 shares worth $547K. The position accounts for 0.16% of the portfolio, ranked #102.

Persistent Asset Partners first reported a position in AVBP in Q4 2025 and has held it in 3 quarters since. 158 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Persistent Asset Partners held 15,734 shares of ArriVent BioPharma worth $547K as of Q2 2026.
  • Persistent Asset Partners bought 7,626 ArriVent BioPharma shares in Q2 2026, an estimated $225K.
  • ArriVent BioPharma made up 0.16% of Persistent Asset Partners's portfolio in Q2 2026, its #102 holding.
  • Persistent Asset Partners first reported a position in ArriVent BioPharma in Q4 2025 and has held it in 3 quarters since.
  • 158 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.